Incanthera PLCAQUIS: INC

Incanthera: Result of AGM

· Issued by Incanthera PLC via RNS

Summary by 6ix AI

Incanthera plc, a UK-based dermatology and oncology company whose current focus is its Skin + CELL luxury skincare brand, said all resolutions were passed at its annual general meeting (AGM) held on November 13, 2026.

Key details

  • Incanthera's shares trade on the Aquis Stock Exchange (AQSE), a UK stock market, under the code INC.

6ix AI wrote this summary from the release below and checked it against the release.

Incanthera PLC
13 November 2026

Goal Group

13 November 2026

Incanthera plc

("Incanthera" or the "Company")

Result of AGM 2026

Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology, announces that at its AGM held on 13 November 2026 all resolutions were duly passed.

The Directors of the Company accept responsibility for the content of this announcement.

For further information please contact:

Incanthera plc

Stuart Robertson, CEO

Laura Brogden, CFO & Company Secretary

Via Vigo Consulting

Cairn Financial Advisers LLP (Aquis Exchange Corporate Adviser)

Jo Turner / Liam Murray / Ed Downes

+44 (0) 20 7213 0880

Stanford Capital Partners Ltd (Broker)

Patrick Claridge / Bob Pountney

+44 (0) 20 7628 5582

Vigo Consulting (Financial PR and Investor Relations)

Jeremy Garcia / Rozi Morris

+44 (0) 20 7390 0230

incanthera@vigoconsulting.com

Notes to Editors

About Incanthera plc

Incanthera is a UK-based, dermatology and oncology therapeutics company focusing on discovery and development of targeted solutions. The Company has developed sophisticated formulation and targeting technology platforms to address previously unavailable options across dermatology and oncology, delivering treatments specifically to a required site, enabling effective ingredients with precision targeting for optimal efficacy.

Identifying and developing innovative solutions to current clinical, commercially relevant unmet needs, Incanthera combines new technology from industry and leading academics, as well as its in-house development team, with its unique targeting delivery platform.

The Company's current focus is Skin + CELL, Incanthera’s unique luxury skincare brand in a range of dermatological applications to meet currently unmet needs in the skincare market.

For more information on the Company please visit: www.incanthera.com

@incantheraplc

About Skin + CELL

Skin + CELL is Incanthera's luxury skincare brand, launched in August 2025. Our ground-breaking formulation and delivery expertise brings scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.

Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.

Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.

www.skinandcell.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Incanthera PLC on 6ix

Story so far

Earlier from Incanthera

All Incanthera news releases